Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2017

View Archived Issues

Stanford University describes novel adrenergic receptor modulators

Saniona selects preclinical candidate for neuropathic pain and chronic itching

Roche's idasanutlin receives U.S. orphan designation for polycythemia vera

FDA names setmelanotide an orphan drug for treating leptin receptor deficiency

Ra Pharmaceuticals reports interim results from phase II study of RA-101495 in PNH

Topline phase IIa results reported from IW-1973 studies

FDA grants orphan drug status to Seres' microbiome therapeutic candidate

CKD273 biomarker panel predicts mortality in patients with diabetic nephropathy

Zebrafish model illuminates role of TTN gene variants in dilated cardiomyopathy

BL-8040 plus high-dose Ara-C improves overall survival in phase IIa study in r/r AML

FDA gives orphan drug designation to SHP-647 for pediatric ulcerative colitis

Lilly initiates phase I study of LY-3381916 alone and in combination with LY-3300054 in solid tumors

Pembrolizumab shows promise for drug-resistant gestational trophoblastic neoplasia

Burosumab shows positive results in phase III study in X-linked hypophosphatemia

ViiV Healthcare UK patents novel HIV integrase inhibitors

La Jolla Pharmaceutical initiates pivotal study of LJPC-401 in patients with beta thalassemia

Mustang Bio signs agreements with Harvard and Beth Israel Deaconess in cancer immunotherapy

Mirati Therapeutics and Array BioPharma describe new mutant KRAS inhibitors

Montreal Neurological Institute and Takeda Canada enter ALS research agreement

Evotec and Ncardia in licensing agreement for stem cell derived cellular disease modeling IP

Roche identifies novel compounds for hepatitis B virus infection

Probiodrug and Crossbeta extend strategic partnership in Alzheimer's biomarkers

Glenmark Pharmaceuticals identifies new nuclear receptor ROR-gamma antagonists

Tioga reports reduced nighttime itching in asimadoline study in atopic dermatitis

Foresee completes phase I studies of MMP-12 inhibitor FP-025

SymBio announces termination of license agreement with The Medicines Company

FDA issues new guidance on 3D printing